These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 25345369

  • 1. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment.
    Cugno M, Tedeschi S, Ardissino G.
    J Thromb Haemost; 2015 Mar; 13(3):485-6. PubMed ID: 25345369
    [No Abstract] [Full Text] [Related]

  • 2. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.
    Wehling C, Kirschfink M.
    J Thromb Haemost; 2014 Sep; 12(9):1437-9. PubMed ID: 24942998
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab
.
    Riddell A, Goodship T, Bingham C.
    Clin Nephrol; 2016 Oct; 86(10):200-2. PubMed ID: 27616760
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients.
    Weitz IC, Deloughery T.
    Br J Haematol; 2018 Oct; 183(1):136-139. PubMed ID: 28857126
    [No Abstract] [Full Text] [Related]

  • 10. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 11. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V.
    Clin J Am Soc Nephrol; 2017 Jan 06; 12(1):50-59. PubMed ID: 27799617
    [Abstract] [Full Text] [Related]

  • 12. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment].
    Knoop M, Haller H, Menne J.
    Internist (Berl); 2018 Aug 06; 59(8):799-804. PubMed ID: 29995248
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].
    Okano M, Matsumoto T, Nakamori Y, Ino K, Miyazaki K, Fujieda A, Sugimoto Y, Tawara I, Yamaguchi M, Ohishi K, Miwa H, Masuya M, Wada H, Katayama N.
    Rinsho Ketsueki; 2018 Aug 06; 59(2):178-181. PubMed ID: 29515070
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
    Sridharan M, Go RS, Willrich MAV.
    J Immunol Methods; 2018 Oct 06; 461():15-22. PubMed ID: 30031798
    [Abstract] [Full Text] [Related]

  • 18. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK, Kavanagh D.
    Transl Res; 2015 Feb 06; 165(2):306-20. PubMed ID: 25468487
    [Abstract] [Full Text] [Related]

  • 19. Eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM, Licht C, Loirat C.
    N Engl J Med; 2013 Oct 03; 369(14):1379-80. PubMed ID: 24088105
    [No Abstract] [Full Text] [Related]

  • 20. Eculizumab in atypical hemolytic-uremic syndrome.
    Ring T.
    N Engl J Med; 2013 Oct 03; 369(14):1377-8. PubMed ID: 24088106
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.